Solventum Corp. (SOLV): price, analyst ratings, earnings and fundamentals
Updated 15 October 2026, 21:45 ET
Solventum Corp. (SOLV) closed at $87.86 on 15 October 2026, up 0.7%. The stock is down 1.1% over one month and up 22.9% over one year. It trades 6.7% below its 52-week high of $94.16. Analysts recorded 8 actions in the last 90 days; the median price target of $100 is 14.4% above the last close. The company last reported on 5 August 2026 for Q2 2026: EPS of $2.55 against an estimate of $1.90, a beat of 34.2%, on revenue of $2.2 billion.
Price and performance
Performance figures use dividend and split adjusted closes over trading sessions, so a one-year move compares the last close with the close 252 sessions earlier. The 52-week range uses the adjusted daily highs and lows of the same window. Read the guide: Momentum, trend and technical indicators.
The live chart with technical indicators is in the app: open SOLV in FundSpec.
Analyst ratings
Over the last 90 days FundSpec recorded 8 analyst actions on SOLV from 6 firms: 7 maintained or reiterated a view and 1 upgrade. Price targets were 6 raised. The most recent targets from 8 firms range from $70 to $105, with a median of $100, 14.4% above the last close.
| Date | Firm | Action | Price target |
|---|---|---|---|
| 14 Sep 2026 | BTIG | Reiterates Buy | $95.00 |
| 6 Aug 2026 | UBS | Maintains Buy | $95.00 to $101.00 |
| 6 Aug 2026 | Piper Sandler | Maintains Overweight | $92.00 to $105.00 |
| 6 Aug 2026 | Wedbush | Maintains Outperform | $94.00 to $101.00 |
| 6 Aug 2026 | Keybanc | Maintains Overweight | $93.00 to $102.00 |
| 6 Aug 2026 | Stifel | Maintains Buy | $90.00 to $100.00 |
| 6 Aug 2026 | BTIG | Maintains Buy | $91.00 to $95.00 |
| 28 Jul 2026 | UBS | Upgrades to Buy from Neutral | $95.00 |
| 9 Jul 2026 | BMO Capital | Initiates Coverage On Market Perform | $81.00 |
| 15 May 2026 | Wedbush | Initiates Coverage On Outperform | $94.00 |
A price target is one firm's twelve-month view, and the median across firms is a steadier reading than any single call. Upgrades and downgrades matter more when they change a rating, not only a target. Read the guide: What analyst ratings and price targets actually tell you.
Every action with the firm's history is in Analyst Ratings.
Earnings
The next report is scheduled for 5 November 2026 after the close for Q3 2026, with EPS expected at $1.35 on revenue of $1.9 billion. Solventum Corp. beat the EPS estimate in 8 of its last 8 reported quarters.
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Q2 2026 | 5 Aug 2026 | $1.90 | $2.55 | +34.21% | $2.2B |
| Q1 2026 | 5 May 2026 | $1.35 | $1.48 | +9.63% | $2.0B |
| Q4 2025 | 26 Feb 2026 | $1.50 | $1.57 | +4.67% | $2.0B |
| Q3 2025 | 6 Nov 2025 | $1.43 | $1.50 | +4.90% | $2.1B |
| Q2 2025 | 7 Aug 2025 | $1.45 | $1.69 | +16.55% | $2.2B |
| Q1 2025 | 8 May 2025 | $1.22 | $1.34 | +9.84% | $2.1B |
| Q4 2024 | 27 Feb 2025 | $1.32 | $1.41 | +6.82% | $2.1B |
| Q3 2024 | 7 Nov 2024 | $1.39 | $1.64 | +17.99% | $2.1B |
An earnings surprise is the reported EPS against the consensus estimate on the day. The price reaction depends as much on guidance and on what was already priced in as on the surprise itself. Read the guide: Earnings season: estimates, surprises and price reaction.
Estimates, confirmed dates and alerts for every company are in Earnings.
Fundamentals
On a trailing twelve month basis the company shows revenue growth of N.A., a gross margin of N.A., an operating margin of N.A. and a return on equity of N.A..
Margins and returns say how much of each dollar of sales becomes profit and how hard the balance sheet is working; leverage and liquidity say how much room the company has when conditions turn. Read the guide: A practical guide to discounted cash flow valuation.
Fair value, peer multiples and the full statement history are in the app: open SOLV in FundSpec.
SEC filings
The latest filing is a 10-Q from 5 August 2026.
| Filed | Form | Document |
|---|---|---|
| 5 Aug 2026 | 10-Q | View on sec.gov |
| 5 May 2026 | 10-Q | View on sec.gov |
| 27 Feb 2026 | 10-K | View on sec.gov |
| 6 Nov 2025 | 10-Q | View on sec.gov |
| 8 Aug 2025 | 10-Q | View on sec.gov |
| 9 May 2025 | 10-Q | View on sec.gov |
| 28 Feb 2025 | 10-K | View on sec.gov |
| 8 Nov 2024 | 10-Q | View on sec.gov |
| 9 Aug 2024 | 10-Q | View on sec.gov |
| 10 May 2024 | 10-Q | View on sec.gov |
Company profile
- Exchange
- NYSE
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Headquarters
- ST. PAUL, Minnesota
- Chief executive
- Bryan C. Hanson
- Employees
- 22,000
- Website
- www.solventum.com/en-us/home/
- SEC CIK
- 0001964738
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
Sector and peers
Solventum Corp. is part of the Manufacturing sector, which FundSpec tracks across 1 company.
Companies in the same industry by market capitalization:
MDLN Medline Inc.GEHC GE HealthCare Technologies Inc.
Put two of them side by side in Compare.
In FundSpec: the fair value estimate, the momentum reading, relative valuation against sector and industry peers, unusual options activity and AI model signals for SOLV are available to subscribers, with the same screen in the iOS and Android apps.
Open SOLV in FundSpec